TISIDB

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus
Domain	PF11934 Domain of unknown function (DUF3452) PF01858 Retinoblastoma-associated protein A domain PF01857 Retinoblastoma-associated protein B domain PF08934 Rb C-terminal domain
Function	Key regulator of entry into cell division. Directly involved in heterochromatin formation by maintaining overall chromatin structure and, in particular, that of constitutive heterochromatin by stabilizing histone methylation. Recruits and targets histone methyltransferases KMT5B and KMT5C, leading to epigenetic transcriptional repression. Controls histone H4 'Lys-20' trimethylation. Probably acts as a transcription repressor by recruiting chromatin-modifying enzymes to promoters. Potent inhibitor of E2F-mediated trans-activation. Forms a complex with adenovirus E1A and with SV40 large T antigen. May bind and modulate functionally certain cellular proteins with which T and E1A compete for pocket binding. May act as a tumor suppressor.

> Gene Ontology [ TOP ]
Biological Process	GO:0019216 regulation of lipid metabolic process GO:0043550 regulation of lipid kinase activity
Molecular Function	GO:0003682 chromatin binding GO:0008134 transcription factor binding GO:1990841 promoter-specific chromatin binding
Cellular Component	GO:0005667 transcription factor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04110 Cell cycle hsa04350 TGF-beta signaling pathway
Reactome	R-HSA-1640170: Cell Cycle R-HSA-69278: Cell Cycle, Mitotic R-HSA-69231: Cyclin D associated events in G1 R-HSA-1538133: G0 and Early G1 R-HSA-69236: G1 Phase R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-453279: Mitotic G1-G1/S phases R-HSA-2173796: SMAD2/SMAD3 R-HSA-162582: Signal Transduction R-HSA-170834: Signaling by TGF-beta Receptor Complex R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04110 Cell cycle
hsa04350 TGF-beta signaling pathway

Reactome

R-HSA-1640170: Cell Cycle
R-HSA-69278: Cell Cycle, Mitotic
R-HSA-69231: Cyclin D associated events in G1
R-HSA-1538133: G0 and Early G1
R-HSA-69236: G1 Phase
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-453279: Mitotic G1-G1/S phases
R-HSA-2173796: SMAD2/SMAD3
R-HSA-162582: Signal Transduction
R-HSA-170834: Signaling by TGF-beta Receptor Complex
R-HSA-6791312: TP53 Regulates Transcription of Cell Cycle Genes
R-HSA-6804114: TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-2173793: Transcriptional activity of SMAD2/SMAD3

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between RBL1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of RBL1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of RBL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.132	0.58
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.254	0.806
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.415	0.597
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.39	0.164
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.43	0.771
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.342	0.858
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.061	0.857
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.188	0.876
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.432	0.722
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.285	0.61
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.051	0.946
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.239	0.00705

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of RBL1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	4.1	3.3	0.61
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	5.1	2.3	0.647
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	33.3	0	33.3	0.0365
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of RBL1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of RBL1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by RBL1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of RBL1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of RBL1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between RBL1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	RBL1
Name	retinoblastoma-like 1
Aliases	p107; cp107; 107 kDa retinoblastoma-associated protein; cellular protein 107; retinoblastoma-like 1 (p107); ......
Chromosomal Location	20q11.23
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting RBL1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse RBL1